Periscope Capital’s Humacyte HUMA Stock Holding History

Periscope Capital’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-450,000	Closed	-$4.58M	–	573
2020 Q4	$4.58M	Buy	+450,000	New	+$4.46M	0.24%	158

Other funds holding HUMA

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

WRBC

W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Periscope Capital's HUMA Position: Q1 2021 in Review

Periscope Capital sold out of Humacyte (HUMA) in Q1 2021, closing a stake of 450,000 shares — an estimated $4.58M sold.

Periscope Capital first reported a position in HUMA in Q4 2020 and held it in 1 quarter. The position peaked at $4.58M in Q4 2020. 23 funds tracked by Wall St. Rank hold HUMA as of Q1 2021.

Periscope Capital reported no remaining Humacyte position as of Q1 2021 after selling out during the quarter.
Periscope Capital sold 450,000 Humacyte shares in Q1 2021, an estimated $4.58M.
Periscope Capital first reported a position in Humacyte in Q4 2020 and held it in 1 quarter.
Periscope Capital's Humacyte position peaked at $4.58M in Q4 2020.
23 funds tracked by Wall St. Rank held Humacyte as of Q1 2021.

Based on Periscope Capital's 13F filing for Q1 2021, filed 14 May 2021.